LEXX Lexaria Bioscience Corp.: Business Value

The market valuation dynamics for Lexaria Bioscience (LEXX) stand at 2.23, driven by the monetization of its proprietary delivery system through licensing agreements with industry behemoths. However, trade restrictions and political conflicts hinder the international implementation of the method, blocking the operations of foreign laboratories. Regular partner payments ensure cash flow stability, creating a reliable financial foundation without sharp declines.

LEXX (Lexaria Bioscience Corp) Total Company Value history from 11/23/2025 to 10/27/2026

Lexaria Bioscience Corp. (LEXX) - metric breakdowns and financial figures

- price and consensus price forecast:

Market Price Lexaria Bioscience Corp|LEXX - Consensus Target

- market capitalization data:

Market Capitalization Lexaria Bioscience|LEXX - Real Price to Acquire Entire Company

- book capitalization data:

Equity per Share Lexaria Bioscience|LEXX - Company Book Value|Market Capitalization to Net Assets lexariabioscience.com|LEXX - Company Total Assets

- debt and liquidity data:

All Debt to Shareholders' Equity Ratio Lexaria Bioscience|LEXX - Long-Term Debt to Capital|Short-Term Debt to Capital Lexaria Bioscience Corp|LEXX - Company Debts|Debt to Net Assets Ratio Lexaria Bioscience

Comprehensive company analysis:Lexaria Bioscience (LEXX)

Original product of Lexaria Bioscience Corp.

A qualitative asset assessment requires an analysis of the total business value, accounting for not only market capitalization but also net debt. This metric determines the actual cost of acquiring a company by combining the market value of shares with debt obligations minus liquidity. The trend on the enterprise value chart reflects the market consensus regarding the value of all corporate resources. For Lexaria Bioscience (LEXX), this metric assesses the commercialization potential of the DehydraTECH platform. It is critical for investors to correlate value growth with achievements in the bioavailability of GLP-1 drugs.

Competitor analysis for Lexaria Bioscience

HLN - Total Enterprise Value|Kenvue Corp (KVUE) - Real Price to Acquire Entire Company|Verona Pharma Inc. (VRNA) - Business Value|Real Price to Acquire Entire Company Jyong Biotech Ltd|LGND (ligand.com) - Business Value|Total Company Value Amneal AMRX|Full Business Value Perrigo Company PLC|Alvotech Corp (ALVO) - Enterprise Value|Value Adjusted for Debt and Cash Liquidia Inc. (LQDA)|Enterprise Value GLPG (Galapagos NV)|anipharmaceuticals.com - Enterprise Value|Total Company Value MannKind (MNKD)|AMPH: Value Adjusted for Debt and Cash|PCRX (Pacira) - Total Company Value|ARS Corp (SPRY) - Real Price to Acquire Entire Company|TBPH (Theravance Biopharma) - Enterprise Value|Enterprise Value aquestive.com (AQST)|scPharmaceuticals Inc. (SCPH) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash TECX (tectonictx.com)|TNXP: Total Company Value|SXTC - Total Enterprise Value|Real Price to Acquire Entire Company Eupraxia Pharma EPRX|BHST - Aggregate Business Value|Enterprise Value eXoZymes EXOZ|Oramed Pharmaceuticals Inc. (ORMP) - Value Adjusted for Debt and Cash|Enterprise Value ENTX (Entera Bio Ltd)|Total Enterprise Value HYFT|ABVC BioPharma (ABVC) - Total Company Value|Value Adjusted for Debt and Cash CPIX (cumberlandpharma.com)|Total Company Value Quantum BioPharma QNTM|Total Company Value FibroGen Inc FGEN|TELO (Telomir Pharma) - Enterprise Value|Rani Therapeutics (RANI) - Total Enterprise Value|Real Price to Acquire Entire Company synergychc.com|Rallybio (RLYB) - Business Value|PULM (Pulmatrix) - Enterprise Value|Enterprise Value PTHL|Aptorum Group Limited (APM) - Total Company Value|Value Adjusted for Debt and Cash Lyra Therapeutics Inc (LYRA)|Enterprise Value IBO|Company Buyout Price TNF Pharmaceuticals Inc. TNFA|cbdMD Corp - Enterprise Value|PainReform Ltd (PRFX) - Enterprise Value|Real Price to Acquire Entire Company altamiratherapeutics.com CYTO|Lipella Pharma (LIPO) - Value Adjusted for Debt and Cash|Enterprise Value OptiNose, Inc.|Total Company Value pieris.com|PROC (Procaps) - Enterprise Value|Company Buyout Price PTPI (Petros Pharmaceuticals Inc)|QLI: Total Company Value|ACELYRIN Inc. - Total Enterprise Value|Total Company Value TFFP (TFF Pharmaceuticals)